Research programme: stroke therapy - Biofrontera
Latest Information Update: 14 Mar 2007
At a glance
- Originator Biofrontera AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 28 May 2003 Preclinical trials in Stroke in Germany (unspecified route)